JP2011137015A5 - - Google Patents

Download PDF

Info

Publication number
JP2011137015A5
JP2011137015A5 JP2011027692A JP2011027692A JP2011137015A5 JP 2011137015 A5 JP2011137015 A5 JP 2011137015A5 JP 2011027692 A JP2011027692 A JP 2011027692A JP 2011027692 A JP2011027692 A JP 2011027692A JP 2011137015 A5 JP2011137015 A5 JP 2011137015A5
Authority
JP
Japan
Prior art keywords
use according
acid
polyunsaturated fatty
per
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011027692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011137015A (ja
Filing date
Publication date
Priority claimed from US08/943,576 external-priority patent/US6080787A/en
Application filed filed Critical
Publication of JP2011137015A publication Critical patent/JP2011137015A/ja
Publication of JP2011137015A5 publication Critical patent/JP2011137015A5/ja
Pending legal-status Critical Current

Links

JP2011027692A 1997-02-21 2011-02-10 壊死性全腸炎の発生を減少させるための方法及び組成物 Pending JP2011137015A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US08/804,700 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/825,314 1997-03-28
US08/943,576 1997-10-03
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP53687198A Division JP2001516343A (ja) 1997-02-21 1998-02-19 壊死性全腸炎の発生を減少させるための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2011137015A JP2011137015A (ja) 2011-07-14
JP2011137015A5 true JP2011137015A5 (enExample) 2012-04-26

Family

ID=27122714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011027692A Pending JP2011137015A (ja) 1997-02-21 2011-02-10 壊死性全腸炎の発生を減少させるための方法及び組成物

Country Status (5)

Country Link
US (1) US6080787A (enExample)
JP (1) JP2011137015A (enExample)
KR (1) KR100439166B1 (enExample)
AR (1) AR011160A1 (enExample)
IL (1) IL150490A (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
EP1181870A1 (en) * 2000-08-22 2002-02-27 Belovo Eggs & Egg Products Manufactured lipid emulsion having an improved balanced dietary source of vitamin F
US6864242B2 (en) * 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
US6620427B2 (en) * 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
AU2002309856B2 (en) * 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
EP2275101A1 (en) * 2001-05-14 2011-01-19 Martek Biosciences Corporation Polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes, and its uses
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2004002232A1 (en) * 2002-06-28 2004-01-08 Theuer Richard C Fat compositions for infant formula and methods therefor
PT1542670E (pt) * 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
EP1589834B1 (en) * 2003-02-05 2007-04-11 N.V. Nutricia Enteral composition for the prevention and/or treatment of sepsis
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2530170A1 (en) * 2003-06-24 2005-01-06 University Of Kansas Medical Center Infant formula
GB2422373B (en) 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) * 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
AU2006251562B2 (en) * 2005-05-23 2012-03-22 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
WO2008081989A1 (ja) * 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
US8652508B2 (en) 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
EP2200443B2 (en) * 2007-09-17 2021-06-30 Cornell University Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
EP2258216A1 (en) * 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
ES2804258T3 (es) 2010-12-31 2021-02-05 Abbott Lab Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
CA2822490C (en) 2010-12-31 2020-03-31 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US8802650B2 (en) 2010-12-31 2014-08-12 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
ES2667393T3 (es) 2010-12-31 2018-05-10 Abbott Laboratories Oligosacáridos de leche humana para modular inflamación
MY191538A (en) 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
MY166945A (en) 2010-12-31 2018-07-25 Abbott Lab Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
CN107019701B (zh) 2010-12-31 2020-07-28 雅培制药有限公司 使用人乳低聚糖来降低婴儿、幼儿或儿童的坏死性小肠结肠炎的发病率的方法
EP2734210B1 (en) 2011-07-22 2017-11-22 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CA2846603A1 (en) 2011-08-29 2013-03-07 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2014078544A1 (en) * 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
BR112015014561A2 (pt) 2012-12-18 2017-07-11 Abbott Lab fortificante de leite humano concentrado líquido contendo proteína hipoalergênica e luteína
WO2017117121A1 (en) * 2015-12-28 2017-07-06 Abbott Laboratories Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092121B1 (en) * 1982-04-12 1987-12-16 Board Of Regents, The University Of Texas System Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) * 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) * 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4950656A (en) * 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
ES2157898T3 (es) * 1991-01-24 2001-09-01 Martek Corp Aceites microbianos y usos de los mismos.
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
ATE167983T1 (de) * 1994-10-05 1998-07-15 Milupa Gmbh & Co Kg Phospholipidhaltige fettmischung mit lcp- fettsäuren
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) * 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US6200624B1 (en) * 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids

Similar Documents

Publication Publication Date Title
Teoh et al. Erratum to “Genetically improved farmed Nile tilapia and red hybrid tilapia showed differences in fatty acid metabolism when fed diets with added fish oil or a vegetable oil blend”
JP2019147836A5 (enExample)
Betancor et al. Influence of dietary docosahexaenoic acid in combination with other long-chain polyunsaturated fatty acids on expression of biosynthesis genes and phospholipid fatty acid compositions in tissues of post-smolt Atlantic salmon (Salmo salar)
Wang et al. Dietary carbohydrate levels and lipid sources modulate the growth performance, fatty acid profiles and intermediary metabolism of blunt snout bream Megalobrama amblycephala in an interactive pattern
PH12014501828A1 (en) Methods, compositions, and devices for supplying dietary fatty acid needs
Nguyen et al. Growth performance and immune status in common carp Cyprinus carpio as affected by plant oil-based diets complemented with β-glucan
PH12013501433A1 (en) High protein nutritional compositions and methods of making and using same
NZ595204A (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
BR112014001907A2 (pt) produção de dha e outros lc-pufas em plantas
JP2011255373A5 (enExample)
RU2017119470A (ru) Способ лечения нейротравмы
JP2008519796A (ja) 脂質混合物含有栄養物
Lemahieu et al. Effect of different microalgal n− 3 PUFA supplementation doses on yolk color and n− 3 LC-PUFA enrichment in the egg
WO2011137160A3 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
US20070254954A1 (en) Composition with Preventive or Improvement Effect on Symptoms or Disesases Associted with Stress-Induced Behavior Disorders
CA2905817A1 (en) Reducing the risk of autoimmune disease
SG10201806517QA (en) Compositions and methods for nutrient delivery
Molnár et al. Fatty acid profile of fillet, liver and mesenteric fat in tilapia (Oreochromis niloticus) fed vegetable oil supplementation in the finishing period of fattening
US20090191306A1 (en) Nutritional composition containing dha, rumenic acid, and gangliosides
RU2013124962A (ru) Композиции и способы доставки питательных веществ
GAO et al. Research advances on function of docosahexaenoic acid-microalgae oil.
Sanders Polyunsaturated fatty acid status in vegetarians
Slomma et al. The effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acids on Δ4-desaturation in HepG2 cells
Brinkworth Omega 3: SDA-an omega of emerging importance in cardiometabolic health
Leaño et al. Thraustochytrids: potential DHA source for marine fish nutrition